SS
ANRO icon

Steve Schonfeld’s Alto Neuroscience ANRO Stock Holding History

Steve Schonfeld’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.8M Buy
+257,631
New +$5.96M 0.02% 533
2024
Q4 		– Sell
-169,801
Closed -$1.94M – 2459
2024
Q3 		$1.94M Buy
+169,801
New +$2.08M 0.01% 894

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Steve Schonfeld's ANRO Position: Q2 2026 in Review

Steve Schonfeld opened a new position in Alto Neuroscience (ANRO) in Q2 2026: 257,631 shares worth $6.8M. The stake represents 0.02% of the portfolio and ranks #533 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in ANRO as recently as Q3 2024.

Steve Schonfeld first reported a position in ANRO in Q3 2024 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Steve Schonfeld held 257,631 shares of Alto Neuroscience worth $6.8M as of Q2 2026.
  • Alto Neuroscience was a new Steve Schonfeld position in Q2 2026.
  • Alto Neuroscience made up 0.02% of Steve Schonfeld's portfolio in Q2 2026, its #533 holding.
  • Steve Schonfeld first reported a position in Alto Neuroscience in Q3 2024 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.